Bluejay Diagnostics, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; unaudited consolidated results. Bluejay is a clinical-stage diagnostics company developing rapid whole-blood tests on its Symphony platform, including an IL-6 test for critical-care settings. The products do not yet have FDA marketing authorization, and the company reported no cartridge sales or revenue.
Key financial results
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Revenue | No sales or revenue reported | No sales or revenue reported |
| Research and development | $1.335 million | $1.355 million |
| General and administrative | $1.087 million | $1.177 million |
| Sales and marketing | $6,424 | $148,046 |
| Total operating expenses / operating loss | $2.428 million | $2.680 million |
| Other income, net | $99,640 | $139,729 |
| Net loss | $2.328 million | $2.540 million |
| Net loss per share, basic and diluted | $0.99 | $2.49 |
| Net cash used in operating activities | $2.296 million | $2.934 million |
Gross margin and other revenue-based margins are not meaningful because the company reported no revenue. Management attributed lower R&D expense mainly to reduced technology-transfer work, partly offset by higher clinical-trial costs; lower G&A to capital-preservation measures and reduced professional services; and the decline in sales and marketing to reduced spending. Other income fell primarily due to lower interest income and lower NanoHybrids-related income.
Balance sheet and funding
- At March 31, 2024, cash and cash equivalents were $2.661 million, versus $2.209 million at December 31, 2023. Total assets were $5.075 million and current liabilities were $1.526 million.
- Total liabilities were $1.708 million, including operating and finance lease liabilities; the filing does not report conventional borrowings or other debt.
- Operating cash use was partly offset by $2.784 million of net financing cash, chiefly from the January 2024 public offering. Investing cash use was $35,433; cash increased by $452,653 during the quarter.
- The January offering generated $3.5 million gross proceeds and included common stock, prefunded warrants, and five-year warrants. The company recorded $444,950 of issuance costs in its equity statement. Shares issued and outstanding rose to 2,688,448 at quarter-end from 1,239,140 at year-end; 2,904,448 shares were outstanding on May 1, 2024. Warrants and future equity issuance may add dilution.
- Accumulated deficit was $29.279 million. No dividend or profitability guidance was provided.
Material developments, outlook, and risks
- Going concern and liquidity: Management says material additional capital is needed in the imminent near term to continue operations, and that absent funding the company is likely to run out of available cash in the near term. The board had not identified financing or strategic alternatives it considered viable, and the company had no financing commitments. If financing is unavailable, the board could pursue Chapter 7 liquidation; management does not expect common shareholders to recover material value in that event. The filing does not provide a definitive cash-runway date.
- Clinical and regulatory plans: Bluejay shifted away from COVID-19 studies toward sepsis. It initiated multicenter SYMON studies in Q1 and reported preliminary SYMON-I findings associating baseline IL-6 with in-hospital and 28-day mortality; management said baseline SOFA score did not predict those outcomes in the analyzed cohort. Final analysis is pending. Subject to remaining a going concern, the company plans to use SYMON-I results to inform a validation study and targets a 510(k) submission in 2025. Management says cash constraints have slowed clinical work and already delayed the regulatory timeline; further delays or abandonment are possible.
- Nasdaq listing: The company received notice on February 28, 2024 that its share price had failed the $1.00 minimum bid-price requirement. It had until August 26, 2024 to regain compliance, subject to possible extension and eligibility. The company said publicly held market value was approximately $1.25 million on May 9, 2024, versus a $1 million minimum; a further decline could create an additional deficiency. Shareholders authorized the board to implement a reverse split, which the board was evaluating.
- Commercial and execution risks: FDA authorization is required before U.S. marketing. The company faces competition, technological change, dependence on key personnel, inflation and supply-chain risks. Toray royalties are generally 7.5% of applicable cartridge net sales after first sale; there were no such sales through March 31.
- Other disclosures: No legal proceedings were reported. Management concluded disclosure controls were effective as of March 31, 2024 and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether Bluejay secures near-term financing or a viable strategic alternative, and the resulting effect on dilution, operations, and the going-concern warning.
- Cash use and remaining liquidity in subsequent filings; the filing does not specify how long cash will last.
- Completion and final results of SYMON-I, progress and funding for SYMON-II, and whether the stated 2025 510(k) target remains achievable.
- Nasdaq bid-price and public-float market-value compliance status, including any extension, reverse split, or delisting notice.
- Actual exercise of outstanding warrants and the resulting share count and potential dilution.